Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Technology · ·
$11.62
▼ $0.20 (-1.7%)
Market data updated: 09/20 12:24 PM
News analyzed: 09/20/2026
Market Cap
$2.90B
Day Range
$11.50 - $11.82
52-Week Range
$9.58 - $19.98
Beta
—
Next Earnings
10.11.2026
Support
$9.58
Resistance
$16.81
CLBT is a stock from the Technology sector — Software, hardware, chip, and computing-services companies — revenue tied to the pace of innovation and upgrade cycles.
-35.0% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 1/12 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
MACD
MACD histogram is positive — rising momentum
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 4.8% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
46
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
27
Risk
34
Sentiment
98
Fundamental
No data available
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Cellebrite DI Ltd. highlights its expansion into high-security sectors, emphasizing cybersecurity and military applications. The company announced its subsidiary, Cellebrite Federal Solutions, achieved **CMMC Level 2** certification for federal operations, while its **Guardian platform** earned **IRAP PROTECTED** status for Australian government use. Additionally, Cellebrite launched the **C-TEK**, a portable tactical forensics kit for military intelligence, and plans upcoming investor events. Analysts also note its strong recurring revenue and net retention, though leadership changes and guidance adjustments have drawn attention.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Cellebrite DI Ltd.. News trend score: 98. Reason: 8 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
17
🎯 Conviction (vs. Emotion)
50
Psychology
21
Fundamentals
—
Technical
27
Valuation
—
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-9%
Market Narrative
61
Fundamental Reality
50
Narrative Gap
+11
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for CLBT is dominated by **loss aversion**, as evidenced by the prolonged negative trajectory and muted trading activity. Investors appear hesitant to exit positions despite the downtrend, consistent with a reluctance to realize losses. The narrative gap is neutral, meaning perceptions align with reality, but the dominant psychological state suggests a defensive stance. The key open question is whether this reluctance will persist or if a catalyst—like a breakout in peers—could shift the dynamic. The low volume and lack of volatility further reinforce cautious, risk-averse positioning.
Updated: 09/09/2026, 03:25 AM
What could change this?
👥 What the crowd believes
"Cellebrite Federal Solutions, Inc. (CFSI) achieved the advanced Cybersecurity Maturity Model Certification (CMMC) Level 2 accreditation"
"Cellebrite Guardian completed an assessment under the Infosec Registered Assessors Program (IRAP) at the PROTECTED classification level"
"Cellebrite launched the Cellebrite Tactical Extraction Kit (C-TEK), a ruggedized, all-in-one mobile forensics field kit for military teams"
"Cellebrite DI says Genesis Platform now available to enterprises, expanding globally"
📈 12D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 76/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between methodologies that prioritize macro trends and cyclical positioning versus those that demand deep fundamental or behavioral scrutiny. Charles Mackay and Howard Marks (Market Cycle) both score near-perfectly, seeing it as a low-risk, early-to-mid-cycle opportunity with no crowd-driven mania—highlighting their focus on avoiding bubbles and valuing market context. Meanwhile, Samuel Armstrong Nelson and Jack Schwager also endorse it, with Nelson noting a favorable cycle position and Schwager praising its disciplined setup, reinforcing a consensus among cyclical and trend-following investors. However, the sharp contrast comes from methodologies like Loeb, Veblen, and Housel, which flag it as high-risk, volatile, or growth-chasing—reflecting their skepticism toward speculative or emotionally driven moves. Even Graham, Fisher, and Lynch can’t form a clear verdict due to insufficient data, underscoring how this stock’s ambiguity leaves fundamentalists hesitant, while trend and cycle investors remain bullish.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 76
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 70
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 62
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 55
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 46
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 38
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 36
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 21
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 20
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 7 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 8 positive, 12 neutral, 0 negative out of the last 20 articles.
Yahoo · 17.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 4.9.2026
PR Newswire · 4.9.2026
Yahoo · 2.9.2026
CNW Group · 2.9.2026
SeekingAlpha · 2.9.2026
Yahoo · 1.9.2026
PR Newswire · 1.9.2026
Yahoo · 26.8.2026
PR Newswire · 26.8.2026
Insider Monkey · 21.8.2026
Motley Fool · 20.8.2026
MT Newswires · 19.8.2026
PR Newswire · 19.8.2026
CNW Group · 19.8.2026
Insider Monkey · 18.8.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Cellebrite DI Ltd. (CLBT) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for CLBT specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
CLBT's technical score is 27/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: ATR: 4.8% of price; Calmar: 0.26 (3y annualized return 15.5% / max drawdown 59.8%); Price is below the 50-day average.
StockIQ has no recorded dividend payment history for CLBT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 23 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Hogan Thomas E. | Open Market Sale | 25.8.2026 | 765,249 | -25,299 | $11.29 |
| Hogan Thomas E. | Open Market Sale | 25.8.2026 | 25,299 | -25,299 | $11.29 |
| GEE DAVID NICHOLAS | Open Market Sale | 24.8.2026 | 135,281 | -4,323 | $11.36 |
| GEE DAVID NICHOLAS | Open Market Sale | 24.8.2026 | 4,323 | -4,323 | $11.36 |
| Jewell Marcus | Open Market Sale | 21.8.2026 | 427,128 | -12,562 | $11.24 |
| GEE DAVID NICHOLAS | Open Market Sale | 21.8.2026 | 139,604 | -2,198 | $11.24 |
| Jewell Marcus | Open Market Sale | 21.8.2026 | 12,562 | -12,562 | $11.24 |
| GEE DAVID NICHOLAS | Open Market Sale | 21.8.2026 | 2,198 | -2,198 | $11.24 |
| GEE DAVID NICHOLAS | Open Market Sale | 12.8.2026 | 230 | -230 | $16.07 |
| Hogan Thomas E. | Open Market Sale | 12.8.2026 | 139,713 | -139,713 | $15.39 |
| Jewell Marcus | Open Market Sale | 12.8.2026 | 411 | -411 | $16.07 |
| GEE DAVID NICHOLAS | Open Market Sale | 12.8.2026 | 141,802 | -230 | $16.07 |
| Jewell Marcus | Open Market Sale | 12.8.2026 | 439,690 | -411 | $16.07 |
| Hogan Thomas E. | Open Market Sale | 12.8.2026 | 790,548 | -139,713 | $15.39 |
| Hogan Thomas E. | Grant/Award from Employer | 11.8.2026 | 339,484 | +339,484 | — |
| Hogan Thomas E. | Grant/Award from Employer | 11.8.2026 | 930,261 | +339,484 | — |
| Barter David | Open Market Sale | 8.7.2026 | 41,734 | -41,734 | $16.38 |
| Barter David | Open Market Sale | 8.7.2026 | 334,219 | -41,734 | $16.38 |
| Hogan Thomas E. | Open Market Sale | 2.7.2026 | 103,188 | -103,188 | $15.76 |
| Hogan Thomas E. | Open Market Sale | 2.7.2026 | 590,777 | -103,188 | $15.76 |
| GEE DAVID NICHOLAS | Open Market Sale | 21.5.2026 | 3,430 | -3,430 | $13.15 |
| GEE DAVID NICHOLAS | Open Market Sale | 21.5.2026 | 2,243 | -2,243 | $13.10 |
| GEE DAVID NICHOLAS | Open Market Sale | 21.5.2026 | 145,462 | -2,243 | $13.10 |
| GEE DAVID NICHOLAS | Open Market Sale | 21.5.2026 | 142,032 | -3,430 | $13.15 |
| Jewell Marcus | Open Market Sale | 18.5.2026 | 12,658 | -12,658 | $12.77 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
8,294,839 shares short as of 2026-08-31 · vs. 8,150,644 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
25.8% of trading volume this week was short selling, vs. 53.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology